ZeroStack Corp Dossier - Source-backed chat

ZeroStack Corp

ZSTKNASDAQ

SectorFinancials

IndustryAsset Management & Custody Banks

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.81Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $104.8M

Shares Outstanding 21.8M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ZeroStack Corp. (formerly Flora Growth Corp.) has undergone a dramatic strategic pivot from a cannabis-focused operator to a decentralized AI treasury and AI-focused asset management company. While its legacy pharmaceutical distribution business (Phatebo GmbH) provides a baseline of commercial activity—recently securing up to $14.7 million in purchase orders—the company's financial performance is highly volatile and heavily exposed to digital assets. In Q1 2026, ZeroStack reported a net loss of $36.7 million, driven primarily by a $60.7 million loss from changes in the fair value of its digital assets (primarily 0G Tokens). Although the recent closing of its private cryptocurrency financing transaction consolidates 142.2 million 0G Tokens, the extreme volatility of the crypto market and substantial historical shareholder dilution warrant a cautious 'Hold' stance until the company demonstrates stable monetization of its AI staking model and consistent execution of its pharmaceutical contracts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$11.00

Mean target$11.00

High · most bullish analyst$11.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$11.0020%

The bear case is triggered by a prolonged downturn in the cryptocurrency market, leading to further severe fair value write-downs of the 0G Token treasury (which represents approximately 85% of total assets). Additionally, Phatebo GmbH fails to secure the necessary financing to fulfill its $14.7 million in purchase orders, leading to contract cancellations. Continued cash burn and further dilutive equity raises push the stock toward new historical lows.

Base CaseCentral scenario

$11.0055%

Matches the consensus mean

The base case assumes that ZeroStack's staking revenues remain highly variable due to token price fluctuations, offsetting steady but low-margin pharmaceutical distribution revenues. The company continues to face high operational overhead and integration challenges from its rapid restructuring. Share price remains constrained by the lack of profitability and historical dilution, trading close to its current levels with moderate recovery as the market digests the newly consolidated 0G Token assets.

Bull CaseUpside scenario

$11.0025%

The bull case relies on a rapid appreciation of the 0G Token and the broader decentralized AI ecosystem, leading to substantial staking rewards (which generated $2.8 million in Q1 2026 at an attractive APY). Concurrently, Phatebo GmbH successfully executes the entire $14.7 million in pharmaceutical purchase orders, providing robust non-dilutive cash flow to fund further digital asset acquisitions. Under this scenario, the company's massive discount to its asset base narrows significantly.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First Nasdaq-listed asset management company offering direct exposure to decentralized AI infrastructure.
Consolidated ownership of 142.2 million native 0G Tokens following the successful closing of the Texas Blocker transaction.
Established pharmaceutical distribution footprint in Germany via Phatebo GmbH, providing recurring commercial activity and a recent $14.7 million order pipeline.

Key Investment Risks

Extreme balance sheet exposure to digital asset price volatility, with 0G Tokens representing approximately 85% of total assets.
Substantial historical shareholder dilution, including a 320% increase in shares outstanding over the past year.
Severe operational losses, highlighted by a $36.7 million net loss in Q1 2026 and a massive EPS miss in Q4 2025.

Thesis Invalidation Triggers

A drop in the value of 0G Tokens that wipes out the remaining treasury value.
Failure to obtain the necessary financing to fulfill the German pharmaceutical purchase orders.
Regulatory crackdowns on staking validators or digital asset treasury structures by US or Canadian authorities.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.